The benefit of both ipilimumab plus nivolumab and relatlimab plus nivolumab was shown to be independent of key factors such as PD-L1 status, although both combinations showed their benefit, particularly in melanoma with PD-L1 expression of less than 1% (relatlimab/nivolumab vs Nivolumab: HR 0. Here, CD274 is linked to melanoma.